The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials.

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials.

Item
http://www.wikidata.org/entity/Q34268266
c-Met as a Target for Personalized TherapyClinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials.Abdominopelvic inflammatory myofibroblastic tumor that metastasized to the vertebrae and liver: A case report and review of the literatureMetastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report.Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancerMight radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studiesIs there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.Pharmacokinetics of crizotinib in NSCLC patients.Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments.Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.Clinicopathological and molecular epidemiological study of lung cancer patients seen at a tertiary care hospital in Northern India.The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.Crizotinib-induced toxicity in an experimental rat model.Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients.The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis
P2860

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials.

Item
http://www.wikidata.org/entity/Q34268266
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The efficacy and safety of cri ...... a-analysis of clinical trials.
@ast
The efficacy and safety of cri ...... a-analysis of clinical trials.
@en
The efficacy and safety of cri ...... a-analysis of clinical trials.
@nl
type
label
The efficacy and safety of cri ...... a-analysis of clinical trials.
@ast
The efficacy and safety of cri ...... a-analysis of clinical trials.
@en
The efficacy and safety of cri ...... a-analysis of clinical trials.
@nl
prefLabel
The efficacy and safety of cri ...... a-analysis of clinical trials.
@ast
The efficacy and safety of cri ...... a-analysis of clinical trials.
@en
The efficacy and safety of cri ...... a-analysis of clinical trials.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P478
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
The efficacy and safety of cri ...... a-analysis of clinical trials.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P478
P577
P5875
P6179
P698
P921
P932